Free Trial
OTCMKTS:LZAGY

Lonza Group (LZAGY) Stock Price, News & Analysis

Lonza Group logo
$63.41 +0.02 (+0.03%)
As of 03/28/2025 03:59 PM Eastern

About Lonza Group Stock (OTCMKTS:LZAGY)

Key Stats

Today's Range
$63.34
$63.98
50-Day Range
$60.68
$68.20
52-Week Range
$52.23
$68.29
Volume
67,952 shs
Average Volume
52,909 shs
Market Capitalization
$45.80 billion
P/E Ratio
N/A
Dividend Yield
0.30%
Price Target
N/A
Consensus Rating
Strong Buy

Company Overview

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. This segment also supports customers across various aspects of design, development, and manufacturing, including particle engineering and drug product packaging. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies; offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. This segment also provides Cocoon platform, a closed automated system for patient-scale cell therapy manufacturing; and specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.

Remove Ads

Lonza Group Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
25th Percentile Overall Score

LZAGY MarketRank™: 

Lonza Group scored higher than 25% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Earnings Growth

    Earnings for Lonza Group are expected to grow by 15.43% in the coming year, from $1.88 to $2.17 per share.

  • Price to Earnings Growth Ratio

    Lonza Group has a PEG Ratio of 2.01. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Lonza Group has a P/B Ratio of 4.30. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.00% of the float of Lonza Group has been sold short.
  • Short Interest Ratio / Days to Cover

    Lonza Group has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Lonza Group has recently increased by 50.70%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Lonza Group has a dividend yield of 0.30%, which is in the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Lonza Group does not have a long track record of dividend growth.

  • Dividend Sustainability

    Based on earnings estimates, Lonza Group will have a dividend payout ratio of 8.76% next year. This indicates that Lonza Group will be able to sustain or increase its dividend.

  • Read more about Lonza Group's dividend.
  • Percentage of Shares Shorted

    0.00% of the float of Lonza Group has been sold short.
  • Short Interest Ratio / Days to Cover

    Lonza Group has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Lonza Group has recently increased by 50.70%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Lonza Group has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.82 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Lonza Group this week, compared to 1 article on an average week.
  • Search Interest

    1 people have searched for LZAGY on MarketBeat in the last 30 days.
  • MarketBeat Follows

    Only 27 people have added Lonza Group to their MarketBeat watchlist in the last 30 days. This is a decrease of -10% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Lonza Group insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.07% of the stock of Lonza Group is held by insiders.

  • Percentage Held by Institutions

    Only 0.04% of the stock of Lonza Group is held by institutions.

  • Read more about Lonza Group's insider trading history.
Receive LZAGY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lonza Group and its competitors with MarketBeat's FREE daily newsletter.

LZAGY Stock News Headlines

Lonza price target raised to CHF 640 from CHF 610 at RBC Capital
LZAGF Lonza Group AG
Trump’s Great Society
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
Lonza downgraded to Equal Weight from Overweight at Morgan Stanley
Lonza price target raised to CHF 744 from CHF 645 at Deutsche Bank
Lonza price target raised to CHF 710 from CHF 630 at Barclays
See More Headlines

LZAGY Stock Analysis - Frequently Asked Questions

Lonza Group's stock was trading at $58.78 at the start of the year. Since then, LZAGY stock has increased by 7.9% and is now trading at $63.41.
View the best growth stocks for 2025 here
.

The following companies are subsidiaries of Lonza Group: Octane Biotech, Micro-Macinazione, Capsugel, PharmaCell, InterHealth Nutraceuticals, Triangle Research Labs, Diacon Technologies, and more.

Shares of LZAGY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Today
3/31/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Tobacco products
Sub-Industry
N/A
Current Symbol
OTCMKTS:LZAGY
Employees
18,000
Year Founded
1897

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
33.73
P/E Growth
2.01
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$7.47 billion
Cash Flow
$1.95 per share
Price / Cash Flow
32.54
Book Value
$14.76 per share
Price / Book
4.30

Miscellaneous

Free Float
721,756,000
Market Cap
$45.80 billion
Optionable
Not Optionable
Beta
1.02

Social Links

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?

Get This Free Report

This page (OTCMKTS:LZAGY) was last updated on 3/31/2025 by MarketBeat.com Staff
From Our Partners